EU Sees Drop In Pay-For-Delay Deals On Generics
The European Commission released a report Wednesday showing that the use of so-called pay-for-delay settlements between brand-name drugmakers and generics companies continues to decline, dropping to 3 percent of the industry's...To view the full article, register now.
Already a subscriber? Click here to view full article